MV for radiotherapy · Mechanical ventilation for radiotherapy
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2020-10-01 → 2022-09-30
- EU contribution
- €187,572
- Participants
- 1
- Scheme
- MSCA-IF
Lines connect the coordinator with its partners.
Results in brief
Mechanical ventilation for radiotherapy
Radiotherapy remains a major treatment for most tumour types and it takes minutes to delivery each radiotherapy dose. The major problem is that patients continue to breathe during these minutes of treatment, so all tumours in the chest and abdomen move with breathing during treatment. This respiratory motion necessitates having to irradiate healthy tissue surrounding the tumour in order to guarantee tumour irradiation. The principal side effects of radiation are: first the damage to all nearby healthy tissue (that limits the duration of any one treatment session), secondly the particular damage to nearby vital organs at risk (usually major blood vessels, airways and gastrointestinal tract). Chest and abdominal cancer treatment is a major burden in Western healthcare medicine so improvement in its delivery is of major importance to society. In the United Kingdom I previously developed 2 potentially major advances in respiratory motion management. First to use non-invasive mechanical ventilation in conscious, unmedicated patients to regularize their breathing pattern. This makes constant the size and timing of each breath. Hence it could be much easier for radiotherapy machines to target tumours accurately and to avoid hitting healthy tissue. Secondly, to prolong breath-hold duration by 5 fold by combining hypocapnia induced by mechanical ventilation with breathing 60% oxygen. Hence respiratory motion could be greatly reduced and potentially abolished. The overall scientific and training objectives of the project were to collaborate with a range of radiotherapy technicians (RTTs), medical physicists and oncologists to • Train Netherlands staff to deliver my techniques of non-invasive mechanical ventilation to regularize patients breathing and of prolonged breath-holds • Train healthy volunteers and patients in the Netherlands to accept non-invasive mechanical ventilation • Use magnetic resonance imaging (MRI) on volunteers and patients to collect data to quantify the improved management of internal motion of relevant structures in the chest and abdomen • Use this motion quantification to demonstrate objectively the reductions in tumour motion during mechanical ventilation compared to current treatment during spontaneous breathing • Use simulated treatment plans to quantify the reductions in estimated radiation dose to healthy tissue that mechanical ventilation will achieve and hence make the case for clinical implementation of mechanical ventilation • Disseminate this information to relevant clinical staff (radiotherapy technicians [RTTs], medical physicists and medical oncologists) and patient groups to encourage adoption of mechanical ventilation
Data: CORDIS, © European Union
Project objective
One of the greatest challenges for modern radiotherapy is ventilation causing motion of tumours and surrounding healthy structures. Technically, modern radiation delivery systems enable in principle very accurate radiation targeting of the tumour and avoiding radiation damage to healthy tissue. However, to deliver sufficient dose to a continuously and irregularly moving tumour, it is necessary to irradiate the tumour with a large margin. Currently such a large margin means irradiating a volume of healthy tissue that is about equal to that of the tumour itself. The healthy tissue damage is itself problematic. But it also prohibits further raising the radiation dose to the tumour to enhance the probability of tumour destruction and thus patient survival. I have invented the use of non-invasive mechanical ventilators to revolutionise radiotherapy delivery, by prolonging breath-hold duration beyond 5 minutes and by reducing and regularising breathing movements. I have demonstrated this works with breast cancer patients. To support its clinical adoption it is now necessary to train other staff to use mechanical ventilation, demonstrate it works with other cancer patient groups, measure the reductions in internal movement of tumours and healthy structures, show how these would produce superior treatment plans and that all this works in another European hospital. My career goal is for me to use the evidence derived from the fellowship to fund the introduction of non-invasive mechanical ventilators first back in our own department (Birmingham, UK), then for me to lead a multi-centre evaluation trial across Europe and finally to lead its introduction into radiotherapy practice throughout Europe.
Original text from CORDIS.
Participants
- ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM · AmsterdamCoordinatorNetherlands
Links
Data: CORDIS, © European Union
